Last edition
News about "Julian Beach"
MHRA Approves Olezarsen (Tryngolza) for Familial Chylomicronemia Syndrome
MHRA approves olezarsen (tryngolza) for adults with Familial Chylomicronemia Syndrome with subcutaneous injection administration.
Julian Beach | 13/04/2026 | By News Bureau
MHRA Approves Bayer's Sevabertinib for HER2-Mutated Advanced Lung Cancer
Sevabertinib, a targeted therapy for HER2-mutated lung cancer, has been approved by the UK regulator to expand treatment options for advanced-stage patients.
Julian Beach | 04/04/2026 | By News Bureau
MHRA Clears Deuruxolitinib (Leqselvi) by Sun Pharma for Severe Alopecia Areata in Adults
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib (Leqselvi) for treating severe Alopecia Areata in adults, granting authorisation to Sun Pharma UK via the International Recognition Procedure (IRP).
Julian Beach | 13/03/2026 | By News Bureau
The UK regulator has approved Inluriyo (imlunestrant tosylate) for adults with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations after prior hormone therapy failure.
Julian Beach | 26/02/2026 | By News Bureau | 117
MHRA Approves Brensocatib as First Targeted Treatment for Non-Cystic Fibrosis Bronchiectasis in UK
UK regulator grants marketing authorisation to brensocatib (Brinsupri) for patients aged 12 and above with recurrent non-cystic fibrosis bronchiectasis flare-ups.
Julian Beach | 24/02/2026 | By News Bureau | 262
MHRA Approves New mRNA COVID-19 Booster
The new approved vaccine, Zapomeran (Kostaive) is cleared for adults aged 18 years and above.
Julian Beach | 05/01/2026 | By News Bureau | 237
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy